Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
Abstract The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the ga...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.70013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850239988171538432 |
|---|---|
| author | Clifford R. Jack Ana Graf Samantha C. Burnham Erin G Doty Hans J. Moebius Philip Montenigro Eric Siemers Kaycee M. Sink Leslie M. Shaw Charlotte Thim Hansen Kristin R. Wildsmith Simin Mahinrad Maria C. Carrillo Christopher J. Weber |
| author_facet | Clifford R. Jack Ana Graf Samantha C. Burnham Erin G Doty Hans J. Moebius Philip Montenigro Eric Siemers Kaycee M. Sink Leslie M. Shaw Charlotte Thim Hansen Kristin R. Wildsmith Simin Mahinrad Maria C. Carrillo Christopher J. Weber |
| author_sort | Clifford R. Jack |
| collection | DOAJ |
| description | Abstract The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the gap between research and clinical care. Although implementation feasibility may vary across regions and settings, improving the availability and accuracy of biomarkers, especially plasma biomarkers, is expected to enhance the applicability of these criteria in clinical practice. The Fall 2023 Alzheimer's Association Research Roundtable (AARR) meeting served as a forum for gathering industry perspectives and feedback on these revised criteria, ensuring that the new criteria inform research, clinical trial design, and clinical care. In this article, we outline a summary of the newly proposed “Revised Criteria for Diagnosis and Staging of AD: AA Workgroup” and provide highlights from the AARR meeting in fall 2023. Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the Revised Criteria for Diagnosis and Staging of AD: AA Workgroup, and gather industry perspectives and feedback on these revised criteria before its publication. The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the AA's Workgroup represent a significant milestone, offering objective measures for the biological and staging of AD and bridging the gap between research and clinical care. Improving the availability and accuracy of biomarkers, especially blood‐based biomarkers (BBMs) is expected to improve clinical research and enhance the applicability of these criteria in clinical practice. |
| format | Article |
| id | doaj-art-1b4ac7654126477d8e3a81dea69d935a |
| institution | OA Journals |
| issn | 2352-8737 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj-art-1b4ac7654126477d8e3a81dea69d935a2025-08-20T02:01:00ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372024-10-01104n/an/a10.1002/trc2.70013Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practiceClifford R. Jack0Ana Graf1Samantha C. Burnham2Erin G Doty3Hans J. Moebius4Philip Montenigro5Eric Siemers6Kaycee M. Sink7Leslie M. Shaw8Charlotte Thim Hansen9Kristin R. Wildsmith10Simin Mahinrad11Maria C. Carrillo12Christopher J. Weber13Department of Neurology Mayo Clinic Rochester Minnesota USANovartis Pharma AG Basel SwitzerlandEli Lilly and Company Boston Massachusetts USAEli Lilly and Company Indianapolis Indiana USAAthira Pharma Inc. Bothell Washington USAEli Lilly and Company Boston Massachusetts USAAcumen Pharmaceuticals Zionsville Indiana USAGenentech Inc South San Francisco California USADepartment of Pathology and Laboratory Medicine Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USAMedical & Science Novo Nordisk A/S Søborg DenmarkNeurology Business Group Eisai Inc Nutley New Jersey USAAlzheimer's Association Chicago Illinois USAAlzheimer's Association Chicago Illinois USAAlzheimer's Association Chicago Illinois USAAbstract The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the gap between research and clinical care. Although implementation feasibility may vary across regions and settings, improving the availability and accuracy of biomarkers, especially plasma biomarkers, is expected to enhance the applicability of these criteria in clinical practice. The Fall 2023 Alzheimer's Association Research Roundtable (AARR) meeting served as a forum for gathering industry perspectives and feedback on these revised criteria, ensuring that the new criteria inform research, clinical trial design, and clinical care. In this article, we outline a summary of the newly proposed “Revised Criteria for Diagnosis and Staging of AD: AA Workgroup” and provide highlights from the AARR meeting in fall 2023. Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the Revised Criteria for Diagnosis and Staging of AD: AA Workgroup, and gather industry perspectives and feedback on these revised criteria before its publication. The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the AA's Workgroup represent a significant milestone, offering objective measures for the biological and staging of AD and bridging the gap between research and clinical care. Improving the availability and accuracy of biomarkers, especially blood‐based biomarkers (BBMs) is expected to improve clinical research and enhance the applicability of these criteria in clinical practice.https://doi.org/10.1002/trc2.70013Alzheimer's disease biomarkersAlzheimer's disease diagnosisAlzheimer's disease imagingAlzheimer's disease stagingAlzheimer's diseaseamyloid positron emission tomography |
| spellingShingle | Clifford R. Jack Ana Graf Samantha C. Burnham Erin G Doty Hans J. Moebius Philip Montenigro Eric Siemers Kaycee M. Sink Leslie M. Shaw Charlotte Thim Hansen Kristin R. Wildsmith Simin Mahinrad Maria C. Carrillo Christopher J. Weber Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice Alzheimer’s & Dementia: Translational Research & Clinical Interventions Alzheimer's disease biomarkers Alzheimer's disease diagnosis Alzheimer's disease imaging Alzheimer's disease staging Alzheimer's disease amyloid positron emission tomography |
| title | Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice |
| title_full | Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice |
| title_fullStr | Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice |
| title_full_unstemmed | Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice |
| title_short | Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice |
| title_sort | application of the revised criteria for diagnosis and staging of alzheimer s disease drug development and clinical practice |
| topic | Alzheimer's disease biomarkers Alzheimer's disease diagnosis Alzheimer's disease imaging Alzheimer's disease staging Alzheimer's disease amyloid positron emission tomography |
| url | https://doi.org/10.1002/trc2.70013 |
| work_keys_str_mv | AT cliffordrjack applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT anagraf applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT samanthacburnham applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT eringdoty applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT hansjmoebius applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT philipmontenigro applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT ericsiemers applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT kayceemsink applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT lesliemshaw applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT charlottethimhansen applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT kristinrwildsmith applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT siminmahinrad applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT mariaccarrillo applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice AT christopherjweber applicationoftherevisedcriteriafordiagnosisandstagingofalzheimersdiseasedrugdevelopmentandclinicalpractice |